A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Launched by BRISTOL-MYERS SQUIBB · Nov 23, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the safety of a medication called mavacamten for adults in Korea who have a condition known as obstructive hypertrophic cardiomyopathy (oHCM). This is a heart condition that can cause symptoms like shortness of breath and chest pain. The purpose of the study is to understand how well mavacamten works in real-life situations for patients who are already receiving it as part of their treatment.

To participate in this trial, individuals must be 19 years or older and agree to receive mavacamten according to the approved usage in Korea. They also need to provide their consent to join the study. Participants will be closely monitored to ensure their safety while taking the medication. It's important to note that people who are prescribed mavacamten for other reasons not approved in Korea, or those who cannot take it for specific medical reasons, will not be eligible for this study. This trial is currently recruiting participants, and anyone interested should talk to their doctor for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult participants 19 years of age or older
• • Participants who receive mavacamten according to the approved product label
• • Participants who sign the informed consent form
• Exclusion Criteria:
• • Participants who are prescribed mavacamten for therapeutic indications not approved in Korea
• • Participants for whom mavacamten is contraindicated as clarified in Korean prescribing information approved by the Ministry of Food and Drug Safety